JP2024525870A5 - - Google Patents

Info

Publication number
JP2024525870A5
JP2024525870A5 JP2024502640A JP2024502640A JP2024525870A5 JP 2024525870 A5 JP2024525870 A5 JP 2024525870A5 JP 2024502640 A JP2024502640 A JP 2024502640A JP 2024502640 A JP2024502640 A JP 2024502640A JP 2024525870 A5 JP2024525870 A5 JP 2024525870A5
Authority
JP
Japan
Prior art keywords
antibody
antibody according
day
administered
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525870A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/070162 external-priority patent/WO2023001804A1/en
Publication of JP2024525870A publication Critical patent/JP2024525870A/ja
Publication of JP2024525870A5 publication Critical patent/JP2024525870A5/ja
Pending legal-status Critical Current

Links

JP2024502640A 2021-07-19 2022-07-19 抗pla2r自己抗体媒介膜性腎症の治療 Pending JP2024525870A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21186299 2021-07-19
EP21186299.0 2021-07-19
EP21203870.7 2021-10-21
EP21203870 2021-10-21
PCT/EP2022/070162 WO2023001804A1 (en) 2021-07-19 2022-07-19 Treatment of anti-pla2r autoantibody-mediated membranous nephropathy

Publications (2)

Publication Number Publication Date
JP2024525870A JP2024525870A (ja) 2024-07-12
JP2024525870A5 true JP2024525870A5 (cg-RX-API-DMAC7.html) 2025-07-17

Family

ID=82851755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502640A Pending JP2024525870A (ja) 2021-07-19 2022-07-19 抗pla2r自己抗体媒介膜性腎症の治療

Country Status (10)

Country Link
US (1) US20240343822A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373574A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525870A (cg-RX-API-DMAC7.html)
KR (1) KR20240035816A (cg-RX-API-DMAC7.html)
CA (1) CA3225908A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024000146A1 (cg-RX-API-DMAC7.html)
IL (1) IL309940A (cg-RX-API-DMAC7.html)
MX (1) MX2024000872A (cg-RX-API-DMAC7.html)
TW (1) TW202321303A (cg-RX-API-DMAC7.html)
WO (1) WO2023001804A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116535510B (zh) * 2023-06-30 2023-11-10 四川省医学科学院·四川省人民医院 一种抗人pla2r的抗体、试剂盒及其应用
WO2025254179A1 (en) * 2024-06-06 2025-12-11 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
TWI924633B (zh) * 2019-03-15 2026-05-11 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物

Similar Documents

Publication Publication Date Title
JP2022191301A5 (cg-RX-API-DMAC7.html)
JP2022002524A5 (cg-RX-API-DMAC7.html)
JP2021526022A5 (cg-RX-API-DMAC7.html)
JP2024531151A5 (cg-RX-API-DMAC7.html)
JP6278536B2 (ja) 関節炎治療
JP2004510752A5 (cg-RX-API-DMAC7.html)
JP2023524149A5 (cg-RX-API-DMAC7.html)
JP2015514110A5 (cg-RX-API-DMAC7.html)
SCHwARz et al. Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation
JP2023541860A5 (cg-RX-API-DMAC7.html)
JP2025131696A5 (cg-RX-API-DMAC7.html)
RU2010120879A (ru) Антитела против g-белка распираторно-синцитиального вируса (rsv)
JP2023545183A5 (cg-RX-API-DMAC7.html)
JP2023055904A5 (cg-RX-API-DMAC7.html)
JP2021532126A5 (cg-RX-API-DMAC7.html)
JP2023545520A5 (cg-RX-API-DMAC7.html)
JP2024024114A5 (cg-RX-API-DMAC7.html)
JP2024534602A5 (cg-RX-API-DMAC7.html)
JP2022523372A5 (cg-RX-API-DMAC7.html)
JP2024540148A5 (cg-RX-API-DMAC7.html)
JP2024069230A5 (cg-RX-API-DMAC7.html)
JP2021512652A5 (cg-RX-API-DMAC7.html)
JP2021511024A5 (cg-RX-API-DMAC7.html)
JP2025087764A5 (cg-RX-API-DMAC7.html)
JP2022529929A5 (cg-RX-API-DMAC7.html)